EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical translation of human iPSC technologies: advances, safety concerns, and future directions

Sarah Dhaiban, Sanjana Chandran, Mohammed Noshi, Abdulrahim A Sajini

Frontiers in Cell and Developmental Biology · 22.09.2025 · 13

DOI: 10.3389/fcell.2025.1627149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 22.09.2025. Verfasst von Sarah Dhaiban und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Khalifa University of Science, Technology and Research, American University of Sharjah.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human induced pluripotent stem cells (hiPSCs) have opened new possibilities in regenerative medicine, providing a versatile platform for modeling human disorders, testing pharmacological agents, and developing personalized regenerative treatments. By reprogramming adult cells into a pluripotent state, scientists can generate patient-specific cells capable of differentiating into nearly any tissue type. Using the patient’s own cells allows for therapies that are both biologically matched and ethically acceptable, while also reducing the likelihood that the immune system will reject transplanted cells. Despite this promise, translating hiPSCs into routine clinical use has proven challenging, with several practical and biological barriers yet to be overcome. Key concerns include variability in differentiation outcomes, immune responses to allogeneic cells, genetic and epigenetic abnormalities, and the risk of tumor formation. Reliable scale-up under GMP conditions remains a major technical hurdle, and critical questions around long-term engraftment, tissue integration, and immune tolerance are still unresolved. Recent advances, including CRISPR/Cas9 gene editing and AI-guided differentiation, are enhancing iPSC quality and enabling treatments to be tailored to individual patients. Clinical trials are ongoing in areas such as retinal disorders, neurodegenerative diseases, cardiac conditions, and cancer immunotherapy, with early findings suggesting these therapies may be both feasible and safe. However, widespread adoption will require rigorous, long-term evaluation. This review examines the latest progress in hiPSC technology and evaluates its movement toward clinical translation. We highlight the major challenges that continue to limit broader application, particularly those related to safety, large-scale manufacturing, and regulatory oversight, and discuss emerging advances that may help bring iPSC-based therapies closer to routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

HLA-matched iPSC bankscell therapyclinical trialsgene editinginduced pluripotent stem cells (iPSCs)personalized medicineregenerative medicine

Autor:innen und Institutionen

  • Department of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
  • Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
  • Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
  • Department of Biology, Chemistry, and Environmental Sciences, College of Arts and Sciences, American University of Sharjah, Sharjah, United Arab Emirates.

Förderung

  • Khalifa University of Science, Technology and Research
  • American University of Sharjah

Zitieren

APA

Dhaiban, S., Chandran, S., Noshi, M., & Sajini, A. A. (2025). Clinical translation of human iPSC technologies: advances, safety concerns, and future directions. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1627149

Vancouver

Dhaiban S, Chandran S, Noshi M, Sajini AA. Clinical translation of human iPSC technologies: advances, safety concerns, and future directions. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1627149

BibTeX
@article{Dhaiban2025,
  author = {Dhaiban, Sarah and Chandran, Sanjana and Noshi, Mohammed and Sajini, Abdulrahim A},
  title = {Clinical translation of human iPSC technologies: advances, safety concerns, and future directions},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1627149}
}
Kostenlos starten →